Lantheus (LNTH) Scheduled to Post Quarterly Earnings on Thursday

Lantheus (NASDAQ:LNTH) is scheduled to release its earnings data before the market opens on Thursday, May 2nd. Analysts expect Lantheus to post earnings of $1.34 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The business had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. On average, analysts expect Lantheus to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $65.21 on Thursday. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69. Lantheus has a 1 year low of $50.20 and a 1 year high of $100.85. The business has a fifty day simple moving average of $61.13 and a 200 day simple moving average of $62.73. The firm has a market cap of $4.47 billion, a price-to-earnings ratio of 14.01 and a beta of 0.53.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on LNTH shares. JMP Securities reiterated a “market outperform” rating and set a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. Truist Financial reiterated a “buy” rating and set a $82.00 price objective (up from $80.00) on shares of Lantheus in a report on Monday, February 26th. B. Riley increased their price objective on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Finally, StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.71.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The disclosure for this sale can be found here. Insiders have sold 94,545 shares of company stock valued at $6,169,936 over the last three months. 1.50% of the stock is currently owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.